A	O
common	O
human	O
skin	I-DiseaseClass
tumour	I-DiseaseClass
is	O
caused	O
by	O
activating	O
mutations	O
in	O
beta	O
-	O
catenin	O
.	O
A	O
common	O
human	O
skin	O
tumour	O
is	O
caused	O
by	O
activating	O
mutations	O
in	O
beta	O
-	O
catenin	O
.	O
WNT	O
signalling	O
orchestrates	O
a	O
number	O
of	O
developmental	O
programs	O
.	O
In	O
response	O
to	O
this	O
stimulus	O
,	O
cytoplasmic	O
beta	O
-	O
catenin	O
(	O
encoded	O
by	O
CTNNB1	O
)	O
is	O
stabilized	O
,	O
enabling	O
downstream	O
transcriptional	O
activation	O
by	O
members	O
of	O
the	O
LEF	O
/	O
TCF	O
family	O
.	O
One	O
of	O
the	O
target	O
genes	O
for	O
beta	O
-	O
catenin	I-DiseaseClass
/	O
TCF	O
encodes	O
c	O
-	O
MYC	O
,	O
explaining	I-DiseaseClass
why	I-DiseaseClass
constitutive	I-DiseaseClass
activation	O
of	O
the	O
WNT	O
pathway	O
can	O
lead	I-SpecificDisease
to	I-SpecificDisease
cancer	I-SpecificDisease
,	I-SpecificDisease
particularly	I-SpecificDisease
in	I-SpecificDisease
the	I-SpecificDisease
colon	O
.	O
Most	O
colon	O
cancers	O
arise	O
from	O
mutations	O
in	O
the	O
gene	O
encoding	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	I-CompositeMention
)	I-CompositeMention
,	I-CompositeMention
a	I-CompositeMention
protein	I-CompositeMention
required	I-CompositeMention
for	O
ubiquitin	O
-	O
mediated	O
degradation	O
of	O
beta	O
-	O
catenin	O
,	O
but	O
a	O
small	O
percentage	O
of	O
colon	O
and	O
some	O
other	O
cancers	O
harbour	O
beta	O
-	O
catenin	O
-	O
stabilizing	O
mutations	I-DiseaseClass
.	I-DiseaseClass
Recently	I-DiseaseClass
,	O
we	O
discovered	I-SpecificDisease
that	I-SpecificDisease
transgenic	I-SpecificDisease
mice	O
expressing	O
an	O
activated	O
beta	O
-	O
catenin	O
are	O
predisposed	O
to	O
developing	O
skin	O
tumours	O
resembling	O
pilomatricomas	O
.	O
Given	O
that	I-SpecificDisease
the	I-SpecificDisease
skin	I-SpecificDisease
of	O
these	O
adult	O
mice	O
also	O
exhibits	O
signs	O
of	O
de	O
novo	O
hair	O
-	O
follicle	O
morphogenesis	O
,	O
we	O
wondered	O
whether	O
human	O
pilomatricomas	O
might	O
originate	O
from	O
hair	O
matrix	O
cells	O
and	O
whether	O
they	I-DiseaseClass
might	I-DiseaseClass
possess	O
beta	O
-	O
catenin	O
-	O
stabilizing	O
mutations	I-Modifier
.	O
Here	O
,	O
we	O
explore	O
the	O
cell	O
origin	O
and	O
aetiology	I-SpecificDisease
of	I-SpecificDisease
this	I-SpecificDisease
common	O
human	O
skin	O
tumour	O
.	O
We	O
found	O
nuclear	O
LEF	O
-	O
1	O
in	O
the	O
dividing	I-DiseaseClass
tumour	O
cells	O
,	O
providing	O
biochemical	O
evidence	O
that	O
pilomatricomas	O
are	O
derived	O
from	O
hair	O
matrix	O
cells	O
.	O
At	O
least	O
75	O
%	O
of	O
these	O
tumours	O
possess	O
mutations	O
affecting	O
the	O
amino	O
-	O
terminal	O
segment	O
,	O
normally	O
involved	O
in	O
phosphorylation	I-DiseaseClass
-	O
dependent	O
,	O
ubiquitin	O
-	O
mediated	O
degradation	O
of	O
the	O
protein	O
.	O
This	O
percentage	O
of	O
CTNNB1	O
mutations	O
is	O
greater	O
than	O
in	O
all	O
other	O
human	O
tumours	O
examined	O
thus	O
far	O
,	O
and	O
directly	O
implicates	O
beta	O
-	O
catenin	O
/	O
LEF	O
misregulation	O
as	O
the	O
major	O
cause	O
of	O
hair	O
matrix	O
cell	O
tumorigenesis	O
in	O
humans	O
.	O
.	O

HFE	O
mutations	O
analysis	O
in	O
711	O
hemochromatosis	I-Modifier
probands	O
:	O
evidence	O
for	O
S65C	O
implication	O
in	O
mild	O
form	O
of	O
hemochromatosis	I-SpecificDisease
.	I-SpecificDisease
HFE	I-SpecificDisease
mutations	I-SpecificDisease
analysis	I-SpecificDisease
in	I-SpecificDisease
711	I-SpecificDisease
hemochromatosis	I-DiseaseClass
probands	I-DiseaseClass
:	I-DiseaseClass
evidence	I-DiseaseClass
for	I-DiseaseClass
S65C	I-DiseaseClass
implication	I-DiseaseClass
in	O
mild	O
form	O
of	O
hemochromatosis	O
.	O
Hereditary	O
hemochromatosis	O
(	O
HH	O
)	O
is	O
a	O
common	O
autosomal	I-SpecificDisease
recessive	O
genetic	O
disorder	O
of	O
iron	O
metabolism	O
.	O
The	O
HFE	O
candidate	O
gene	O
encoding	O
an	O
HLA	O
class	O
I	O
-	O
like	O
protein	I-Modifier
involved	O
in	O
HH	O
was	O
identified	O
in	O
1996	O
.	O
Two	O
missense	O
mutations	O
have	O
been	O
described	O
C282Y	O
,	O
accounting	O
for	O
80	O
%	I-Modifier
to	O
90	O
%	O
of	O
HH	O
chromosomes	O
,	O
and	O
H63D	O
,	O
which	O
is	O
associated	O
with	O
a	O
milder	O
form	O
of	O
the	O
disease	O
representing	O
40	O
%	O
to	O
70	O
%	O
of	O
non	O
-	O
C282Y	O
HH	O
chromosomes	O
.	O
We	O
report	O
here	O
on	O
the	O
analysis	O
of	O
C282Y	O
,	O
H63D	O
,	O
and	O
the	O
193A	O
-	O
-	O
>	O
T	O
substitution	O
leading	O
to	O
the	O
S65C	O
missense	I-SpecificDisease
substitution	I-SpecificDisease
in	O
a	O
large	O
series	O
of	O
probands	O
and	O
controls	O
.	O
The	O
results	O
confirm	O
that	O
the	O
C282Y	O
substitution	O
was	O
the	I-Modifier
main	O
mutation	O
involved	O
in	O
hemochromatosis	O
,	O
accounting	O
for	O
85	O
%	O
of	O
carrier	O
chromosomes	O
,	O
whereas	O
the	O
H63D	O
substitution	O
represented	O
39	O
%	O
of	O
the	O
HH	O
chromosomes	O
that	O
did	O
not	O
carry	O
the	O
C282Y	O
mutation	O
.	O
In	O
addition	O
,	O
our	O
screening	O
showed	O
that	O
the	O
S65C	O
substitution	I-Modifier
was	O
significantly	O
enriched	O
in	O
probands	O
with	O
at	O
least	O
one	O
chromosome	O
without	I-Modifier
an	O
assigned	O
mutation	O
.	O
This	O
substitution	O
accounted	O
for	O
7	O
.	O
8	O
%	O
of	O
HH	O
chromosomes	O
that	I-SpecificDisease
were	I-SpecificDisease
neither	I-SpecificDisease
C282Y	O
nor	O
H63D	O
.	O
This	O
enrichment	O
of	O
S65C	O
among	O
HH	O
chromosomes	O
suggests	O
that	O
the	O
S65C	O
substitution	O
is	O
associated	O
with	O
the	O
mild	O
form	O
of	O
hemochromatosis	O
.	O

